Integrity Bio announces new manufacturing line

By The Science Advisory Board staff writers

June 9, 2020 -- Integrity Bio announced the validation of its second fill/finish manufacturing line in Thousand Oaks, CA. The plant expansion more than doubles the company's manufacturing capacity.

Integrity Bio provides formulation development, good manufacturing practices fill finish services, and drug delivery technologies to support the biotechnology and pharmaceutical industries.

The expanded manufacturing capacity will help the company meet growing demands and prioritize COVID-19 projects, according to Chief Executive Officer Michael Reilly. The new line will allow the company to fill over 20,000 liquid vials in a single batch.

Bio-Techne releases product for manufacturing
Bio-Techne has released GMP ProDots Proteins to support cell and gene therapy manufacturing workflows. The product will allow manufacturers to safely...
Evolugate boosts cells used to manufacture COVID-19 vaccines
The company's technology for improving industrial microorganisms can be used to increase the productivity of host cells needed to produce COVID-19 vaccines,...
AGC to manufacture adjuvant for Novavax COVID-19 vaccine
AGC Biologics announced it is partnering with Novavax for large-scale good manufacturing practices production of critical components for Novavax's coronavirus...
AGC acquires commercial manufacturing facility
Contract development and manufacturing organization AGC Biologics has purchased a large-scale biopharmaceutical manufacturing facility in Boulder, CO.

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter